Table 1.

Demographic and Clinicopathologic Characteristics of 485 Patients Who Underwent Resection of Colorectal Liver Metastases

Characteristic	Value
Patient factor
Age, y, median (IQR)	55 (46–62)
Sex, n (%)
Male	274 (56.5)
Female	211(43.5)
ASA score ≥ 3, n (%)	418 (86.2)
Primary lesion factor, n (%)
Location, n (%)
Colon	333 (68.7)
Rectum	152 (31.3)
T category ≥ 3, n (%)*	420 (86.6)
Lymph node metastasis, n (%)*	333 (68.7)
Liver metastasis clinical factor
Prehepatectomy CEA level, ng/mL, median (IQR)	4.0 (2.2–12.4)
Synchronous metastasis, n (%)	372 (76.7)
Extrahepatic metastasis, n (%)	80 (16.5)
Prehepatectomy chemotherapy, n (%)	439 (90.5)
> 6 cycles	139 (28.7)
Oxaliplatin-containing regimen	362 (74.6)
Irinotecan-containing regimen	103 (21.2)
Anti-VEGF agent-containing regimen	345 (71.1)
Anti-EGFR agent-containing regimen	38 (7.8)
Liver metastasis histopathologic factor
Tumor number, median (IQR)	2 (1–4)
Maximum tumor size, cm, median (IQR)	2.5 (1.5–4.0)
R1 surgical margin, n (%)	98 (20.2)
Pathologic response, n (%)*	236 (48.7)
Somatic mutation, n (%)
BRAF	11 (2.3)
RAS†	246 (50.7)
TP53†	336 (69.3)
APC	253 (52.2)
PIK3CA	79 (16.3)

^*Data missing on T category for 6 patients, lymph node metastasis for 15 patients, and pathologic response for 19 patients.

^†RAS/TP53 co-mutation, 155 (32.0%)

IQR, interquartile range; ASA, American Society of Anesthesiologists; CEA, carcinoembryonic antigen; VEGF, vascular endothelial growth factor; EGFR, epidermal growth factor receptor